Clinical Oncology
Volume 18, Issue 6 , Pages 493-496 , August 2006

Carbogen Breathing Combined with Radical Radiotherapy in Advanced Head and Neck Cancer Patients with Severe Co-morbidities

  • H. Vees
    • ,
  • A.S. Allal

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: Dr Abdelkarim S. Allal, Division de Radio-oncologie, Hôpitaux Universitaires de Genève, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland. Tel: +41-22-3827124/090; Fax: +41-22-3827117.

Received 20 May 2005 ,Revised 27 March 2006 ,Accepted 20 April 2006.

References 

  1. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 2000;355:949–959
  2. Sminia P, Hartmann KA, Schneider CJ, et al. Radiosensitizing effect of carbogen breathing during pulsed irradiation of the rat R1H tumor. Acta Oncol. 2001;40:870–874
  3. Kaanders JH, Bussink J, van der Kogel AJ. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol. 2002;3:728–737
  4. Allal AS, de Pree Ch, Dulguerov P, Bieri S, Maire D, Kurtz JM. Avoidance of treatment interruption: an unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?. Int J Radiat Oncol Biol Phys. 1999;45:41–45
  5. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  6. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  7. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol. 1997;44:111–121
  8. Kuhnt T, Becker A, Pigorsch S, et al. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I–II trial. Strahlenther Onkol. 2003;179:673–681
  9. Bieri S, Bentzen SM, Huguenin P, et al. Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies. Strahlenther Onkol. 2003;179:390–395
  10. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997;38:285–289
  11. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6:509–518
  12. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  13. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?. Strahlenther Onkol. 2003;179:801–811
  14. Falk SJ, Ward R, Bleehen NM. The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised pO2 histography. Br J Cancer. 1992;66:919–924
  15. Powell ME, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ. Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol. 1999;50:167–171
  16. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and vascularity of head-and-neck tumors as measured by magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;53:1185–1191
  17. Siemann DW, Hill RP, Bush RS. The importance of the pre-irradiation breathing times of O2 and carbogen (5% CO2±95% O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys. 1977;2:903–911
  18. Bussink J, Kaanders JH, Strik AM, van der Kogel AJ. Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescence based fiber-optic probes. Radiother Oncol. 2000;57:21–30
  19. Allal AS, Bieri S, Miralbell R, Marchal F, Lehmann W, Kurtz JM. Feasibility and outcome of a progressively accelerated concomitant boost radiotherapy schedule for head and neck carcinomas. Int J Radiat Oncol Biol Phys. 1997;38:685–689
  20. Allal AS, Taussky D, Mach N, Becker M, Bieri S, Dulguerov P. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience. Int J Radiat Oncol Biol Phys. 2004;58:1431–1436
  21. Bussink J, Stratford MR, van der Kogel AJ, Folkes LK, Kaanders JH. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy. Radiother Oncol. 2002;63:285–291

PII: S0936-6555(06)00165-8

doi: 10.1016/j.clon.2006.04.010

Clinical Oncology
Volume 18, Issue 6 , Pages 493-496 , August 2006

Article Tools